UBS products ›
UBS (Lux) Equity Fund - Biotech (USD) P-acc
|ISIN no.: LU0069152568|
UBS Sector Funds target investors who want to capture opportunities in specific global sectors. Our fund managers utilise UBS's extensive research and portfolio management expertise to identify opportunities arising from difference between the market price of a stock and its intrinsic value.
Actively managed equity portfolio investing worldwide in biotech companies.
Efficient means of exploiting the potential of biotech companies operating in research, product development, production or distribution.
Specialised sector analysts seek out the most attractive stocks in the biotech sector worldwide.
Investment decisions are based on a disciplined investment philosophy and fundamental research.
Easy access to the global biotech sector.
Offers investors broad diversification within the sector.
The fund taps into the knowledge of proven sector specialists.
UBS's proprietary fundamental valuation approach enables the most attractive biotechnology companies to be consistently identified.
Investors benefit from a global investment platform of UBS Asset Management.
UBS Sector Funds invest in equities and may therefore be subject to high fluctuations in value. For this reason, an investment horizon of at least five years and corresponding risk tolerance and capacity are required. As these UBS Funds pursue an active management style, each Fund's performance can deviate substantially from that of its reference index. Focusing intentionally on individual sectors may entail additional risks. All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk).
UBS Equity Funds
UBS Sector Funds
UBS Asset Management
UBS Fund Management (Luxembourg) S.A.
UBS Europe SE, Luxembourg Branch
Day of inception
October 15, 1996
Currency of account
Close of financial year
Issue / redemption
Total expense ratio (TER)
Reference Index / Benchmark
MSCI US Investable Market Biotechnology 10/40 Index (r)
Net asset value
High - last 12 months
Low - last 12 months
Assets of the unit class in mn
Total product assets in mn
Total risk reference index / benchmark
Risk Free Rate
Performance chart (USD-based, as of January 17, 2018)
Indexed, Month-end values
Past performance is not a reliable indicator of future results.
Performance (in %, as of January 17, 2018)
The performance shown does not take account of any commissions, entry or exit charges.
These figures refer to the past. Past performance is not a reliable indicator of future results.
Peer group (as of December 31, 2017)
Fund (USD, in%)
Ø peer group (in %) 1)
Quartile ranking 2)
||Average performance Lipper Global Classification (LGC)
||Quartile 1,2,3,4; e.g.: 1= fund is part of the best 25% of all funds of the peer group
Peer group information. Peer group category used: LGC Equity Sector Biotechnology, based on mutual funds in the "MSCI Europe Developed Markets Universe" ex institutional and insurance funds, ETF's and Pension Trusts. Source and calculation: Lipper, a Thomson Reuters Company
By investment domicile (in %, as of December 29, 2017)
By the 10 largest equity positions (in %, as of December 29, 2017)
Gilead Sciences Inc
Alexion Pharmaceuticals Inc
Vertex Pharmaceuticals Inc
BioMarin Pharmaceutical Inc
Alnylam Pharmaceuticals Inc
By sector (in %, as of December 29, 2017)
Additional fees (e.g. entry or exit fees) may be charged by the Distributor. Please refer to your financial adviser for more details. For a definition of financial terms refer to the glossary available at www.ubs.com/glossary
For marketing and information purposes by UBS. UBS funds under Luxembourg law. Prospectuses, simplified prospectuses or key investor information, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available free of charge from UBS Fund Services (Luxembourg) S.A., P.O. Box 91, L-2010 Luxembourg or from UBS Europe SE, Luxembourg Branch, P.O. Box 2, L-2010 Luxembourg. The fund documentation is available free of charge in English and, where relevant, in one of the local language(s) where the fund is registered. Before investing in a product please read the latest prospectus carefully and thoroughly. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. Commissions and costs have a negative impact on performance. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS AG. Source for all data and charts (if not indicated otherwise): UBS Asset Management
Source for all data and charts (if not indicated otherwise): UBS Asset Management
No responsibility is taken for the correctness of the information provided above.
Important legal information - please read the disclaimer before proceeding.
Products and services in these web pages may not be available for residents of certain nations.
Please consult the sales restrictions relating to the service in question for further information.